Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB1

LILRB1

Brief Information

Name:Leukocyte immunoglobulin-like receptor B1
Target Synonym:Leukocyte Immunoglobulin Like Receptor B1,LIR-1,MIR-7,ILT2,LIR1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Soluble Isoform,PIR-B,Leukocyte immunoglobulin-like receptor 1,MIR7,PIRB,CD85j,Immunoglobulin-like transcript 2,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1,Monocyte/Macrophage Immunoglobulin-Like Receptor 7,CD85 Antigen-Like Family Member J,Myeloid Inhibitory Receptor 7,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

CDJ-H52H4-MALS-HPLC
Human LILRB1, His Tag (Cat. No. ) MALS images

The purity of Human LILRB1, His Tag (Cat. No. CDJ-H52H4) is more than 95% and the molecular weight of this protein is around 52-71 kDa verified by SEC-MALS.

  • Background
    CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    CDJ-H5252-MALS-HPLC
    Human LILRB1, Fc Tag (Cat. No. ) MALS images

    The purity of Human LILRB1, Fc Tag (Cat. No. CDJ-H5252) is more than 95% and the molecular weight of this protein is around 150-185 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human LILRB1, Fc TagHuman LILRB1, Fc Tag (Cat. No. CDJ-H5252) ELISA bioactivity

Immobilized Biotinylated Human IHLA-G & B2M Heterodimer Protein, His,Avitag (Cat. No. HLM-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human LILRB1, Fc Tag (Cat. No. CDJ-H5252) with a linear range of 2-39 ng/mL (Routinely tested).

Customer Reviews

Synonym Name

CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

Background

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes.  CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NGM-707 NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Mesothelioma; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
BND-22 BND-22; SAR-444881 Phase 2 Clinical Biond Biologics Ltd, Sanofi Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message